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Abstract Irreversible electroporation (IRE) is a novel
image-guided ablation technique that is rapidly gaining
popularity in the treatment of malignant tumors located
near large vessels or bile ducts. The presence of metal
objects in the ablation zone, such as Wallstents, is gener-
ally considered a contraindication for IRE, because tissue
heating due to power conduction may lead to thermal
complications. This report describes a 66-year-old female
with a Bismuth–Corlette stage IV unresectable cholangio-
carcinoma with a metallic Wallstent in the common bile
duct, who was safely treated with percutaneous IRE with
no signs for relapse 1 year after the procedure.
Keywords Cholangiocarcinoma/Klatskin 
Irreversible electroporation (IRE)  Electroporation/
methods  Tumor ablation/percutaneous  Ablation
techniques/adverse effects
Introduction
Cholangiocarcinoma accounts for approximately 2 % of all
cancer diagnoses, with an overall incidence of 1.2/100,000
individuals [1]. Two-thirds of cases occur in patients over
the age of 65, with a near ten-fold increase in patients over
80 years of age [2]. Hilar cholangiocarcinomas (Klatskin
tumors) account for up to 25 % of all cholangiocarcinomas
[1]. Complete tumor resection (Bismuth–Corlette type I and
potentially type II and III) offers the only hope for long-term
survival, with 5-year survival rates ranging from 10 to 40
percent [1]. However, because most tumors become symp-
tomatic at a late stage, less than half of the cholangiocarci-
nomas are resectable at time of presentation with a median
survival of less than 6 months for those patients [1, 3]. No
clear clinical benefit has been demonstrated for neoadjuvant
and adjuvant therapies. There is no established standard
palliative chemotherapeutic regimen [2].
Recently, irreversible electroporation (IRE) has been
introduced as a novel technique for image-guided tumor
ablation. With this technique, multiple short, high-voltage
electrical pulses are delivered to the tumor tissue, which
disrupt the cellular membrane and ultimately lead to cell
death through apoptosis [4]. Although results are still
preliminary, for pancreatic and liver tumors, the technique
appears to be tolerated well and early results of efficacy are
promising [5–7]. Clinical studies seem to confirm pre-
clinical animal studies where IRE near the portal triad
rarely leads to biliary complications [4].
The presence of a metallic Wallstent within the abla-
tion zone is generally considered to be an absolute
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contraindication for IRE. If the electric current passes
through the stent, the predicted electric field distribution
may be compromised and extreme current concentration
may result in stent-induced tissue heating, leading to un-
desirable thermal damage to sensitive structures such as
intestines and bile ducts [9, 10]. Also, redistribution of the
electric field may result in an unpredictable shape of the
ablation zone, leading to an incomplete ablation. Com-
mercial electroporation pulse-generators are typically lim-
ited to a 50 A maximum current and surpassing this
threshold leads to a generator hard-reset for recalibration or
component restabilization [8].
Despite this contraindication, uncomplicated IRE-pro-
cedures in previously stented patients with locally ad-
vanced pancreatic carcinoma have been reported (data
presented at CIRSE 2013 by G. Narayanan, University of
Miami, Miller School of Medicine).
Here, a case of percutaneous IRE is presented in a pa-
tient with an unresectable and growing hilar cholangio-
carcinoma for which a palliative metallic Wallstent was
previously placed.
Case Presentation
A 66-year-old female is presented with silent icterus
(bilirubin 89 lm/L, alkaline phosphatasis U/L). Computed
tomography (CT) imaging showed a 30 9 30 9 38 mm
mass in the liver hilum surrounding the common and the
left and right main bile ducts (Bismuth–Corlette type IV)
(Fig. 1A, B). There was no sign of lymph nodal or
metastatic spread and all the blood vessels were patent. An
endoscopic ultrasound (EUS)-guided core needle biopsy of
the lesion confirmed the diagnosis of hilar cholangioade-
nocarcinoma. Because of biliary obstruction, a plastic re-
trievable endoprosthesis was placed and renewed several
times, but due to repeated congestion of the endoprosthesis,
it was eventually replaced for a metallic Wallstent and
bilirubin levels normalized (14 lm/L). After establishing
local disease progression at 3 months, she was referred to
our centre.
The patient was discussed in our weekly multidisci-
plinary hepatobiliary tumor board consisting of a radi-
ologist, interventional radiologist, hepatobiliary surgeon,
medical oncologist, hepato-gastroenterologist, radio-
therapist, and nuclear radiologist. All potential risks and
benefits of IRE near the portal triad with a metallic stent
in situ were carefully outweighed against best supportive
care. Since the stent did not reach into the duodenum, the
risk of damaging the duodenal wall was considered low.
After careful deliberation, the patient opted for IRE and
gave written informed consent.
First, to allow repeated and real-time visualization of
both the tumor and the vessels within the celiac trunk, a
catheter was placed within the common hepatic artery
(Fig. 2). To determine the 3-D measurements of the tumor
and its proximity to other structures, a 40 mL bolus of 1:1
saline diluted contrast material was injected at 4 mL/sec
with a scan delay of 7 and 30 s for the arterial and portal
venous phase CT, respectively (Sensation 64 slice MDCT,
Siemens, Erlangen, Germany). Size and shape, including
a 5 mm margin, determined the number and configuration
of the electrodes [11]. With the patient under general
anesthesia in the supine position, a total of six monopolar
needle electrodes (NanoKnife; AngioDynamics, Latham,
New York) were placed alongside the metallic Wallstent
under CT-fluoroscopy guidance, three on each side
(Figs. 1C, D, 2). The active working length of the elec-
trodes was set at 2 cm. Eight vectors for pulse delivery
were chosen with a minimum and maximum interprobe
distance of 1.6 and 2.5 cm (Fig. 1D). All pulses were
delivered in the absolute refractory period of the heart
with use of electrocardiographic synchronization (Ac-
cusync, Model 72; Milford, CT) to elude the induction of
cardiac arrhythmias. To avoid generalized muscle con-
tractions, additional rocuronium was given to achieve
deep muscle paralysis. First, ten test pulses of 90 lsec
were delivered for each electrode pair with a deliberately
low voltage (750 V/cm) because of the presence of the
Wallstent to verify the delivered current, and avoid a
potential stent-induced overcurrent, which ranged between
13 and 24 A. Next, the voltage was adjusted to 1250 V/
cm after which another ten test pulses were given. The
delivered current appeared consistent for all electrode
pairs and ranged between 24 and 40 A, so subsequently
80 treatment pulses were delivered along each vector.
After removal of all six needles, contrast-enhanced CT
(ceCT) demonstrated a hypodense ablation zone contain-
ing gas bubbles (Fig. 1E). The gas bubbles are presum-
ably caused by the electrolysis of water (H2O) into
oxygen (O2) and hydrogen gas (H2) by the electric current
passing through the tissue [12]. The portal vein and the
surrounding arteries were patent and the intrahepatic bile
ducts appeared unremarkable.
The patient awakened uneventfully in the recovery
unit and was transferred to the ward. The next day she
experienced some nausea and vomiting, which was suc-
cessfully treated with anti-emetics. No pain medication
was required. Venous sampling showed a mild increase
in transaminases (AST from 32 to 53 U/L, ALT from 26
to 52 U/L) with no signs for cholestasis (bilirubin
17 lmol/L). MRI(-DWI) 1 day post-IRE showed an
edematous ablation zone surrounding the Wallstent which
was present in the same location. No complications to the
blood vessels or bile ducts were noticed (Fig. 1F). On the
4th day post-IRE, the patient was discharged in good
clinical condition. Further recovery was uneventful. Four
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months later, follow-up ceCT showed no local tumor
progression or metastatic disease, also no stent compli-
cations were noticed. At six, 9 months, and 1-year
follow-up, ceCT still showed no local tumor progression
or metastatic disease (Fig. 1G, H). She currently remains
in follow-up.
Fig. 1 A Coronal ceCT image
pre IRE with a hilar
cholangiocarcinoma (arrow)
surrounding a metallic
Wallstent present in the
common bile duct. B ceMRI
image demonstrating an
enhancing mass in the liver
hilum surrounding the common
bile duct. C Axial CT image of
two electrodes placed alongside
the Wallstent. D Coronal CT
view demonstrating all six
electrodes and eight electrode
pairs during the ablation (red
lines). E ceCT immediately
after IRE demonstrating patent
vessels and gas bubbles in the
ablated area (arrow). F ceMRI
1 day post-IRE with no signs of
complications. G, H ceCT
6 months and 1 year after IRE
demonstrating no tumor
progression
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Discussion
The electrical pulses administered with IRE destabilize the
cellular membranes and lead to the formation of ‘nano-
pores’ in the lipid bilayer, irreversibly damaging the cell’s
homeostatic mechanism [7]. IRE only affects the mem-
branes of living cells, while preserving the extracellular
matrix constituents that are responsible for the patency of
major vascular and ductal structures and other vulnerable
tissues [17]. Also, ablation success is not impaired by heat-
sink [20]. For these reasons, the technique may be suitable
to treat hilar cholangiocarcinoma.
Because hilar cholangiocarcinomas are often unre-
sectable at presentation, in the majority of cases treatment
focuses on palliation of symptoms. The preferred modality
of palliation is the placement of a stent in the main biliary
duct [16]. Both plastic endoprosthesis and metallic Wall-
stents are used for biliary drainage. Adverse effects, in-
cluding cholangitis, stent occlusion, migration, perforation,
and the need for reinterventions occur more frequently with
plastic stents (39.3 %) than with metal stents (11.8 %) [13–
15]. Therefore, in spite of the high initial cost, metallic
Wallstents are considered more cost-effective for patients
with tumors that are considered unsuitable for surgical
resection.
The effect of metal on tissue temperature during IRE has
recently been analyzed in porcine liver. Dunki-Jacobs et al.
reported a mean maximum change in temperature imme-
diately adjacent to the electrodes of 29.3 C for ablations
with metal stent in situ versus 11.3 C for ablations without
metal stents (p = 0.007) [10]. The effect of smaller
metallic implants on the ablation parameters was evaluated
by Neal et al. [9]. Numerical, ex vivo, and in vivo models
evaluated the influence from multiple metallic bra-
chytherapy seeds on electrical current, electric field, and
temperature in tissue as well as acute histological effects
[9]. There was no significant impact from the presence of
these small conducting seeds on the characteristics influ-
encing the outcome of IRE.
In this specific case, the potential thermal effect on tu-
mor tissue surrounding the stent may actually have been
beneficial in terms of ablation and oncological efficacy for
three reasons. First, since tissue conductivity increases with
an increase in temperature, the zone of irreversibly elec-
troporated tissue may be larger and more complete [8].
Secondly, with an exposure length of several minutes and
the before mentioned peak temperature increases sur-
rounding the stent, the periductal tumor tissue may also
have been irreversibly damaged by heat itself [12]. Thirdly,
although in large part unknown, an increase in tumor
temperature during ablation coincides with a stronger im-
mune response, therefore, a potential systemic abscopal
response may have been elucidated [18]. It remains unclear
to what extent the metal influences the electric field, which
can also lead to a less effective or less predictable ablation
zone. To avoid thermal damage to the duodenal wall, the
use of IRE should be discouraged if the metallic Wallstent
extends into the duodenum.
In conclusion, this case report describes a technically
successful percutaneous IRE procedure of a hilar cholan-
giocarcinoma in the presence of a metallic Wallstent in the
main bile duct. However, before IRE for this indication can
be implemented in the clinical setting, the biophysical ef-
fects of metallic objects within the zone of electroporation,
as well as its safety and efficacy, need to be confirmed in
future translational and clinical studies.
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